15th Feb 2021 11:05
ValiRx PLC - clinical stage drug development company - Enters new agreement with Oxford-based oncology consultant Physiomics PLC, which will supersede the first agreement signed in September 2011.
Under the new agreement, Physiomics will provide the latest version of its virtual tumour technology, which will be used by ValiRx to obtain information from the additional data generated by the completed VAL201 clinical trial.
Physiomics will also help model the use of the VAL201 peptide in endometrosis and coronavirus.
Physiomics for its part will receive a fee capped at GBP6 million of 6% of any future net revenue received by ValiRx relating to its commercialisation of VAL201 and its derivatives in any indications, including prostate cancer, endometriosis and treatment for coronavirus infection.
"This will help in the design and execution of future clinical trials and support discussions with potential new partners. We expect that outputs from the application of Physiomics' technology will be incorporated into scientific publications presenting the results from the VAL201 clinical trial," said Chief Executive Officer Suzy Dilly.
Current stock price: ValiRx at 22.65 pence; Physiomics at 8.16p
Year-to-date change: ValiRx up 16%, Physiomics up 11%
By Dayo Laniyan; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
PhysiomicsValiRx